scholarly journals CANCER PATIENTS

2006 ◽  
Vol 13 (03) ◽  
pp. 344-348
Author(s):  
MOHAMMAD JAWAID SABZWARI ◽  
Muhammad Riaz ◽  
MUKHTAR AHMAD ◽  
Muhammad Umair ◽  
MUHAMMAD TAHIR MAJEED
Keyword(s):  
Sialic Acid ◽  
Carcinoembryonic Antigen ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Age Distribution ◽  
Laboratory Diagnosis ◽  
Cancer Management ◽  
Serum Sialic Acid ◽  
Diagnosis Of Cancer ◽  
Diagnostic Indicator

In the world cancer is one of the leading causes of death. Most cancerswhen detected early, can be potentially cured. Thus early laboratory diagnosis of cancer has great importance inmanagement. The tumor markers are one of the methods of cancer management in use today. Objectives: Tocompare serum sialic acid (SA) and carcinoembryonic antigen (CEA) as tumor markers in different cancer patients.Study Design: Prospective study Setting: Shaikh Zayed Medical Complex, Lahore. Material and Methods: Onehundred and fifty three (153) documented different cancer patients were studied to compare between serum sialic acidand carcinoembryonic antigen as a tumor marker along with fifty controls of matched sex and age distribution between30-85 years. The sialic acid was estimated by colorimetric procedure and carcinoembryonic antigen by EnzymeImmunoassay. Results: The results revealed that mean levels of sialic acid and CEA in cancer patients weresignificantly higher (p<0.05) as compared to controls, considering all malignancies together, or carcinoma,hematological malignancies and sarcoma alone. Statistical analysis showed sialic acid to be more sensitive (p<0.05)than CEA in detection of cancer. Conclusion: Sialic acid was seen to be a good diagnostic indicator as compared toCEA in most cancer patients.

Plasma lipid-bound sialic acid and carcinoembryonic antigen in cancer patients.

1981 ◽  
Vol 27 (10) ◽  
pp. 1737-1739 ◽  
Author(s):  
A M Dnistrian ◽  
M K Schwartz
Keyword(s):  
Sialic Acid ◽  
Carcinoembryonic Antigen ◽  
Cancer Patients ◽  
Lipid Extraction ◽  
Plasma Lipid ◽  
Normal Subjects ◽  
Breast Cancer Patients ◽  
Lung Cancer Patients ◽  
Total Lipid Extraction ◽  
The Individual

Abstract We evaluated lipid-bound sialic acid as a "marker" in cancer patients and assessed the individual and combined value of lipid-bound sialic acid and carcinoembryonic antigen determinations in these patients. Plasma was sampled from 62 normal subjects and 125 cancer patients. Lipid-bound sialic acid was determined by the resorcinol method after total lipid extraction and isolation of the sialolipid fraction from plasma. Neither marker was increased in many breast cancer patients. Carcinoembryonic antigen was increased more commonly and to a greater degree in colon cancer patients and seems to be the preferred marker. Both markers were increased in lung cancer patients and their combined evaluation improved the rate of detection. Lipid-bound sialic acid was increased in more patients with leukemias, lymphomas, Hodgkin's disease, and melanomas, suggesting that it may be a useful biochemical marker in these types of cancer.

Serum Sialic Acid Levels in Lung Cancer Patients

Pharmacology ◽  
1976 ◽  
Vol 14 (1) ◽  
pp. 47-51 ◽  
Author(s):  
F.J. Krolikowski ◽  
K. Reuter ◽  
T.P. Waalkes ◽  
S.M. Sieber ◽  
R.H. Adamson
Keyword(s):  
Lung Cancer ◽  
Sialic Acid ◽  
Cancer Patients ◽  
Lung Cancer Patients ◽  
Serum Sialic Acid

Evaluation of serum sialic acid and carcinoembryonic antigen for the detection of early-stage colorectal cancer

1991 ◽  
Vol 5 (4) ◽  
pp. 247-254 ◽  
Author(s):  
Carmen Tautu ◽  
Jack A. Alhadeff ◽  
David Pee ◽  
Marlene Dunsmore ◽  
Joseph J. Prorok
Keyword(s):  
Colorectal Cancer ◽  
Sialic Acid ◽  
Carcinoembryonic Antigen ◽  
Early Stage ◽  
Serum Sialic Acid

scholarly journals BREAST CANCER

2007 ◽  
Vol 14 (01) ◽  
pp. 98-104
Author(s):  
MUKHTAR AHMAD ◽  
MUHAMMAD TAHIR MAJEED ◽  
MOHAMMAD JAWAID SABZWARI ◽  
Muhammad Riaz ◽  
Muhammad Umair
Keyword(s):  
Breast Cancer ◽  
Sialic Acid ◽  
Breast Carcinoma ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Sensitivity And Specificity ◽  
Colorimetric Method ◽  
Enzyme Linked Immunosorbent Assay ◽  
Breast Cancer Patients

Cancer is a group of diseases with uncontrolled cellular proliferation. Breast cancer accounts for 25% of all cancer deaths in females worldwide. Monoclonal antibodies are used for the detection of tumor markers in order for rapid diagnosis and understanding of the nature of cancer at molecular level. On co-fetal antigens like carcinoembryonic antigen 15-3 (CA 15-3) are a new generation of clinically useful tumor markers. Elevated levels of CA 15-3 are related to stages in primary breast cancer, tumor size and nodal status. Significantly elevated sialic acid concentrations havebeen found in breast cancer patients and show correlation with tumor stage. Although total sialic acid has been used as general cancer marker but its role as diagnostic and prognostic marker has not been reported. Objective: This project was designed to study the sensitivity and specificity of sialic acid in breast cancer patients and was compared to CA 15-3, which is one of the most specific markers of breast cancer. Study design: Comparative study. Setting: Shaikh Zayed Medical Complex. Material and Methods: 66 breast cancer patients and 30 normal individuals (controls) were included in the study to compare serum sialic acid with CA 15-3 as tumor marker. Sialic acid was estimated by colorimetric method while CA 15-3 by Enzyme-Linked Immunosorbent Assay. Results: The sensitivity and specificity of CA 15-3 in breast cancer patients was 62.5% and 80% while that of sialic acid was 62% and 76% respectively. The sensitivity of CA 15-3 and sialic acid in patients with ductal breast carcinoma was 62.5% and 54.16% whereas the specificity of CA 15-3 and sialic acid was 80% and 76% respectively. The sensitivity of CA 15-3 and sialic acid in patients with lobular breast carcinoma was 83.33% and 75% whereas the specificity of CA 15-3 and sialic acid was 80% and 76% respectively. Conclusion: It was concluded that sialic acid can be used as a tumor marker in breast cancer patients and has sensitivity and specificity similar to CA15-3. However, CA 15-3appears to have better predictive value. 

History of the development of tumor markers of the digestive tract cancers

2013 ◽  
Vol 154 (21) ◽  
pp. 810-819 ◽  
Author(s):  
György Miklós Buzás
Keyword(s):  
Carcinoembryonic Antigen ◽  
Tumor Markers ◽  
Tumor Burden ◽  
High Risk Population ◽  
Gene Products ◽  
Therapeutic Success ◽  
Induced Tumors ◽  
History Of ◽  
Diagnosis Of Cancer ◽  
Transplantation Antigens

Tumor markers are gene products which signal the occurrence of tumors in different organs as well as their response to surgery and chemotherapy. The discovery of tumor markers occurred after the demonstration of tumor-specific transplantation antigens in chemically or virally induced tumors in syngenic rodents. The history of currently used tumor markers began in the 1940s, the first discovered being alpha-fetoprotein in 1956, followed by that of carcinoembryonic antigen in 1965. Since then the range of tumor markers has widened continously. Their chemical structure and genetics is now well known. Some may play part in tumor growth and development of metastases. The potential uses of tumor markers are general or high risk population screening, adjunct in diagnosis of cancer, preoperative indicator of tumor burden, indicator of therapeutic success, evidence of postoperative recurrences and use in tumor localization. However, there is no ideal tumor marker fulfilling all the criteria. Isotope-labeled anti-carcinoembryonic antigen antibodies and small molecular E-selectin inhibitors could play a role in the molecular radio- and chemotherapy of colon and pancreatic carcinomas. Orv. Hetil., 2013, 154, 810–819.

Usefulness and Potential Pitfalls of Sialic Acid Determination in Sera of Patients with Ovarian Tumors

1986 ◽  
Vol 1 (1) ◽  
pp. 39-46 ◽  
Author(s):  
Bruno Berra ◽  
Silvana Rapelli ◽  
Gianluigi Monticelli ◽  
Maria Albertina Fighetti ◽  
Ines Della Mea ◽  
...  
Keyword(s):  
Sialic Acid ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Preliminary Data ◽  
Ovarian Tumors ◽  
Serum Sialic Acid ◽  
Methodological Errors ◽  
Acid Determination

Increasing evidence in the literature indicates that serum sialic acid is increased in cancer patients suggesting a possible usefulness of its determination as a tumor marker. However there are many discrepancies in the data reported, probably due to methodological errors, mainly in lipid bound sialic measurement. In this paper we illustrate the results obtained when we applied a method worked out in our laboratory for the determination of total and fractionated sialic acid (lipid and protein bound) to the analysis of sera from patients with ovarian tumors and the preliminary data on the follow up of selected cases. The potential pitfalls in using this relatively new tumor marker will be critically evaluated.

Sign in / Sign up

Export Citation Format

Share Document